Report #2861940

Received Sep 29, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 66 yrs
State: OH
Recovered: Unknown
Vaccinated: Feb 23, 2024
Onset: Feb 23, 2024
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

received a dose of Shingrix on 2-Feb-2024 and a second on 23-Feb-2024; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 66-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included VARICELLA ZOSTER VACCINE RGE (CHO) (SHINGRIX). On 23-FEB-2024, the patient received the 2nd dose of Shingrix. On 23-FEB-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: received a dose of Shingrix on 2-Feb-2024 and a second on 23-Feb-2024). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK receipt date: 16-SEP-2025 Registered pharmacist would like to be contacted via email.